James L. Boyer

Internal Medicine

40 Temple St Ste 1A
New Haven, CT 06510

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 17, 2025

The Utility of Elastography in Discriminating Stages of Liver Fibrosis and Risk Stratification in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

The Utility of Elastography in Discriminating Stages of Liver Fibrosis and Risk Stratification in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

Journal: Journal of magnetic resonance imaging : JMRI

Published: October 21, 2025

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.

Journal: Alimentary pharmacology & therapeutics

Published: October 08, 2025

Liver Lymphatic Dysfunction as a Driver of Fibrosis and Cirrhosis Progression.

Liver Lymphatic Dysfunction as a Driver of Fibrosis and Cirrhosis Progression.

Journal: bioRxiv : the preprint server for biology

Published: January 27, 2025

Conjugated bile acid-driven CD14+CD16+ monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis.

Conjugated bile acid-driven CD14+CD16+ monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis.

Journal: JHEP reports : innovation in hepatology

Published: December 01, 2024

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Journal: Hepatology communications

Published: June 19, 2024

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

Journal: Cells

Published: June 13, 2024

Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.

Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.

Journal: Hepatology (Baltimore, Md.)

Published: January 12, 2024

Pilot study of telehealth delivery of horticultural therapy (TeleHT) as an acceptable intervention and in reducing suicide risk factors in veterans.

Pilot study of telehealth delivery of horticultural therapy (TeleHT) as an acceptable intervention and in reducing suicide risk factors in veterans.

Journal: Complementary therapies in medicine

Published: December 19, 2023

Bile Acid Induced Inflammation and the Role of β-Catenin.

Bile Acid Induced Inflammation and the Role of β-Catenin.

Journal: Cellular and molecular gastroenterology and hepatology

Published: August 15, 2023

Human vascularized bile duct-on-a chip: a multi-cellular micro-physiological system for studying cholestatic liver disease.

Human vascularized bile duct-on-a chip: a multi-cellular micro-physiological system for studying cholestatic liver disease.

Journal: Biofabrication

Published: August 03, 2023

Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in Humans.

Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in Humans.

Journal: Cellular and molecular gastroenterology and hepatology

Published: October 05, 2022

Showing 1-12 of 85

Last Updated: 09/26/2026